Heart
1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
EchoNousWA - Redmond
2 programsCategory 1: Corrective GuidanceN/A1 trial
PLAX EF Manual vs. Automatic MeasurementN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
Vasa TherapeuticsVS-041
EchoNousCategory 1: Corrective Guidance
EchoNousPLAX EF Manual vs. Automatic Measurement
Clinical Trials (3)
Total enrollment: 539 patients across 3 trials
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Start: Nov 2025Est. completion: Jul 202642 patients
Phase 1Recruiting
Kosmos Guidance Performance Evaluation Data Annotation
Start: Jun 2026Est. completion: Sep 202681 patients
N/AActive Not Recruiting
Kosmos PLAX EF Pivotal Study
Start: May 2026Est. completion: Sep 2026416 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 539 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.